Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
1 evidence topic · 1 source
EMBOLD cohort 2: baseline medication use among relutrigine-exposed participants
| Baseline ASMs | Participants |
|---|---|
| 1 to 2 | “17 (33%)” |
| 3 to 6 | “34 (67%)” |